MIRA PHARMACEUTICALS, INC. 8-K

What Happened
MIRA Pharmaceuticals, Inc. (filed 8-K June 8, 2026) announced that Alan Weichselbaum is no longer serving as the company’s Chief Financial Officer and that the board appointed Andriy Mushak as fractional Chief Financial Officer, effective June 6, 2026 (appointment made June 2, 2026). The filing states Mr. Weichselbaum’s departure was not due to any disagreement with the company. Mr. Mushak, CPA, age 43, is a partner at LMAM Consulting Group, LLC and will provide services to MIRA under a consulting agreement between MIRA and LMAM.

Key Details

• Effective date of appointment: June 6, 2026 (board action dated June 2, 2026).
• Consulting arrangement: Mr. Mushak remains employed by LMAM and will serve MIRA under the LMAM consulting agreement.
• Compensation: MIRA will pay $6,000 per month for Mr. Mushak’s services.
• Background: Mushak is a CPA with 20+ years of SEC reporting, accounting, and audit experience (former senior manager in Baker Tilly’s Boston audit practice; co‑founded LMAM in 2025). No family relationships or reportable related‑party transactions were disclosed.

Why It Matters
A CFO change affects oversight of financial reporting and SEC compliance. MIRA’s use of a fractional CFO through a consulting firm suggests a cost‑controlled, possibly interim solution ($6,000/month disclosed) rather than hiring a full‑time executive immediately. The company’s statement that the prior CFO’s departure was not due to disagreement reduces the likelihood of litigation or disclosure issues tied to the change. The consulting agreement is filed as an exhibit to the 8‑K.